Factors affecting interindividual differences in clozapine response: a review and case report

被引:35
作者
Bersani, Francesco Saverio [1 ]
Capra, Enrico [1 ]
Minichino, Amedeo [1 ]
Pannese, Rossella [1 ]
Girardi, Nicoletta [1 ]
Marini, Isabella [1 ]
Delle Chiaie, Roberto [1 ]
Biondi, Massimo [1 ]
机构
[1] Univ Roma La Sapienza, Dept Neurol & Psychiat, Rome, Italy
关键词
clozapine metabolism; therapeutic drug monitoring; CYP450; polymorphisms; drug - drug interactions; D3 RECEPTOR GENE; ARYL-HYDROCARBON RECEPTOR; CYP1A2; GENE; CHRONIC-SCHIZOPHRENIA; SMOKING-CESSATION; CLINICAL-RESPONSE; ALLELIC VARIATION; 5-HT2A RECEPTOR; PLASMA-LEVELS; IN-VITRO;
D O I
10.1002/hup.1191
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Clozapine is the most powerful new-generation antipsychotic. Although this drug leads to great therapeutic benefits, two types of undesirable conditions frequently occur with its use: side effects and resistance to treatment. Therapeutic drug monitoring of clozapine would be very useful to avoid both these situations. The necessity of monitoring the therapy is the result of a wide interindividual variability in the metabolism of clozapine. In this review, we highlight all the conditions underlying this variability, analyzing them one by one. Methods Relevant literature was identified through a search of MEDLINE and PubMed. In addition, the case of a treatment-resistant patient with accelerated metabolism of clozapine is reported as representative of utility of therapeutic drug monitoring in terms of clozapine dose adjustment. Results Genetic polymorphisms of cytochrome P450 enzymes and of neurotransmitter receptors; drug interactions; interactions of clozapine with other substances such as food and drink; smoking; and nonmodifiable variables such as age, ethnicity, and gender have been examined in relation to the existing scientific literature. The laboratory techniques that clinicians could use to identify these variables and adequate therapies are also reviewed. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:177 / 187
页数:11
相关论文
共 74 条
[1]   Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine [J].
Adachi, J ;
Mori, Y ;
Matsui, S ;
Takigami, H ;
Fujino, J ;
Kitagawa, H ;
Miller, CA ;
Kato, T ;
Saeki, K ;
Matsuda, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (34) :31475-31478
[2]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[3]   ASSOCIATION BETWEEN CLOZAPINE RESPONSE AND ALLELIC VARIATION IN 5HT(2A) RECEPTOR GENE [J].
ARRANZ, M ;
COLLIER, D ;
SODHI, M ;
BALL, D ;
ROBERTS, G ;
PRICE, J ;
SHAM, P ;
KERWIN, R .
LANCET, 1995, 346 (8970) :281-282
[4]  
Arranz MJ, 1996, NEUROSCI LETT, V217, P177, DOI 10.1016/0304-3940(96)13094-9
[5]   Pharmacogenetic prediction of clozapine response [J].
Arranz, MJ ;
Munro, J ;
Birkett, J ;
Bolonna, A ;
Mancama, D ;
Sodhi, M ;
Lesch, KP ;
Meyer, JFW ;
Sham, P ;
Collier, DA ;
Murray, RM ;
Kerwin, RW .
LANCET, 2000, 355 (9215) :1615-1616
[6]   Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response [J].
Arranz, MJ ;
Munro, J ;
Sham, P ;
Kirov, G ;
Murray, RM ;
Collier, DA ;
Kerwin, RS .
SCHIZOPHRENIA RESEARCH, 1998, 32 (02) :93-99
[7]   Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia [J].
Basile, VS ;
Masellis, M ;
Badri, F ;
Paterson, AD ;
Meltzer, HY ;
Lieberman, JA ;
Potkin, SG ;
Macciardi, F ;
Kennedy, JL .
NEUROPSYCHOPHARMACOLOGY, 1999, 21 (01) :17-27
[8]   Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population [J].
Bilgen, T. ;
Tosun, O. ;
Luleci, G. ;
Keser, I. .
RUSSIAN JOURNAL OF GENETICS, 2008, 44 (08) :989-992
[9]   Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response [J].
Birkett, JT ;
Arranz, MJ ;
Munro, J ;
Osbourn, S ;
Kerwin, RW ;
Collier, DA .
NEUROREPORT, 2000, 11 (09) :2017-2020
[10]   Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients [J].
Bondolfi, G ;
Morel, F ;
Crettol, SV ;
Rachid, F ;
Baumann, P ;
Eap, CB .
THERAPEUTIC DRUG MONITORING, 2005, 27 (04) :539-543